Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy | Zendy

Sherri Z. Millis | Zendy; Samuel Ejadi | Zendy; Michael J. Demeure | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy

Author(s) -

Sherri Z. Millis,

Samuel Ejadi,

Michael J. Demeure

Publication year - 2015

Publication title -

biomarkers in cancer

Language(s) - English

Resource type - Journals

ISSN - 1179-299X

DOI - 10.4137/bic.s34292

Subject(s) - ercc1 , etoposide , cancer research , mitotane , adrenocortical carcinoma , cish , cisplatin , oncology , population , medicine , biology , chemotherapy , dna repair , in situ hybridization , gene , nucleotide excision repair , genetics , gene expression , environmental health

Current first-line chemotherapy for patients with metastatic adrenocortical cancer (ACC) includes doxorubicin, etoposide, cisplatin, and mitotane with a reported response rate of only 23.2%. New therapeutic leads for patients with refractory tumors are needed; there is no standard second-line treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research